Search

Your search keyword '"Hagleitner, Melanie"' showing total 39 results
Start Over Author "Hagleitner, Melanie"
Sorry, I don't understand your search. ×
39 results on '"Hagleitner, Melanie"'

1. Severe toxicity free survival: physician-derived definitions of unacceptable long-term toxicities following acute lymphocytic leukaemia

Author

Attarbaschi, Andishe, Adams, Madeline R, Andres-Jensen, Liv, Bardi, Edit, Barzilai-Birenboim, Shlomit, Baust, Katja, Bhojwani, Deepa, Boesten, Tineke, Calaminus, Gabriele, Conyers, Rachel, Darlington, Anne-Sophie, de Ville, Maëlle, Escherich, Gabriele, Hagleitner, Melanie, Halsey, Christina, Harila-Saari, Arja, Hou, Jen-Yin, Huang, Ting-Huan, Hudson, Melissa, Jeha, Sima, Jenney, Meriel, Kato, Motohiro, Krawczuk-Rybak, Maryna, Kremer, Leontine, Lautem, Melchior, Liu, Hse-Che, Lopez Lopez, Elixabet, Mateos, Marion, Mlynarski, Wojciech, Möricke, Anja, Muszynska-Roslan, Katarzyna, Niinimaki, Riitta, Pieters, Rob, Piette, Caroline, Raetz, Elizabeth, Ronceray, Leila, Schmiegelow, Kjeld, Toro, Claudia, Trahair, Toby, Valsecchi, Maria Grazia, van der Sluis, Inge, van Litsenburg, Raphaële, Vrooman, Lynda, Weinreb, Sigal, Wiener, Andreas, Winick, Naomi, Yano, Michihiro, Yeh, Ting-Chi, Zapotocka, Ester, Andrés-Jensen, Liv, Hagleitner, Melanie M, van Litsenburg, Raphaele R L, Hudson, Melissa M, Kremer, Leontien, Grazia Valsecchi, Maria, and Vrooman, Lynda M

Published
2021
Full Text
View/download PDF

2. Prophylactic red blood cell transfusions in children and neonates with cancer: An evidence-based clinical practice guideline.

Author

Kruimer, Demi M., Stavleu, Debbie C., Mulder, Renée L., Kremer, Leontien C. M., Tissing, Wim J. E., Loeffen, Erik A. H., Bresters, Dorine, Evers, Janneke H. P., van Gestel, Sjef P. J., Hagleitner, Melanie M., Heitink-Pollé, Katja M. J., Huisman, Elise J., Janssens, Geert O. R., Kuijper, Philip H. M., Mensink, Maarten O., Nijman, Joppe, Noordzij, Jeroen G., Ophorst, Ida, Plieger, Willemijn, and Spijkerman, Judith

Abstract

Background: Red blood cell (RBC) transfusions play an important role in supportive care in children and neonates with cancer. However, in current clinical practice, evidence-based recommendations are lacking on when to administer prophylactic RBC transfusions. To address this gap, a clinical practice guideline (CPG) was developed to systematically review the available evidence and provide recommendations for clinicians. Methods: A systematic literature review in three databases was conducted. The GRADE methodology was used to assess, extract, and summarize the evidence. A multidisciplinary panel of 21 professionals was assembled to ensure comprehensive expertise. If there was insufficient evidence in children with cancer, additional evidence was gathered in general pediatric or adult oncology guidelines, or the panel utilized shared expert opinion to develop a comprehensive CPG. Multiple in-person meetings were conducted to discuss evidence, complete evidence-to-decision frameworks, and formulate recommendations. Results: Four studies including 203 children with all types of cancer, met the inclusion criteria. The expert panel assessed all evidence and translated it into recommendations. In total, 47 recommendations were formulated regarding RBC transfusions in children and neonates with cancer. For instance, specific thresholds for prophylactic RBC transfusions were recommended for children and neonates with cancer who have sepsis, are on ECMO, or are undergoing radiotherapy. Conclusion: This clinical practice guideline presents evidence-based recommendations regarding RBC transfusions in children and neonates with cancer. By providing these recommendations, we aim to guide clinicians and contribute to improving outcomes for children and neonates with cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. NOTCH1 fusions in pediatric T-cell lymphoblastic lymphoma: A high-risk subgroup with CCL17 (TARC) levels as diagnostic biomarker

Author

Pathologie Moleculair, Pathologie Pathologen staf, PMC Medisch specialisten, Genetica, Cancer, Kroeze, Emma, Kleisman, Michelle M., Kester, Lennart A., Scheijde-Vermeulen, Marijn A., Sonneveld, Edwin, Buijs-Gladdines, Jessica G.C., Hagleitner, Melanie M., Meyer-Wentrup, Friederike A.G., Veening, Margreet A., Beishuizen, Auke, Meijerink, Jules P.P., Loeffen, Jan L.C., Kuiper, Roland P., Pathologie Moleculair, Pathologie Pathologen staf, PMC Medisch specialisten, Genetica, Cancer, Kroeze, Emma, Kleisman, Michelle M., Kester, Lennart A., Scheijde-Vermeulen, Marijn A., Sonneveld, Edwin, Buijs-Gladdines, Jessica G.C., Hagleitner, Melanie M., Meyer-Wentrup, Friederike A.G., Veening, Margreet A., Beishuizen, Auke, Meijerink, Jules P.P., Loeffen, Jan L.C., and Kuiper, Roland P.

Published
2024

4. Less restrictions in daily life: a clinical practice guideline for children with cancer.

Author

Stavleu, Debbie C., Mulder, Renée L., Kruimer, Demi M., Kremer, Leontien C. M., Tissing, Wim J. E., Loeffen, Erik A. H., Beek, Laura R., Evers, Janneke H. P., Hagleitner, Melanie M., Martens, Daniëlle H. J., Noordzij, Jeroen G., Ophorst, Ida, Ottens, Janneke R., Plieger, Willemijn, Quaak, Marjolijn S. W., Schuerhoff, Tirza, Spijkerman, Judith, van der Steeg, Alida F. W., van de Wetering, Marianne D., and Wolfs, Tom F. W.

Abstract

Purpose: In current clinical practice, recommendations regarding restrictions in daily life for children with cancer are often lacking or not evidence-based. Critically reviewing the evidence and formulating recommendations are therefore of great importance as social restrictions (e.g., swimming, school attendance, sports) can impair the quality of life of these children severely. Therefore, our aim was to develop a clinical practice guideline for clinicians, children, and their parents regarding social restrictions in children with cancer. Methods: A comprehensive multidisciplinary panel was assembled, comprising 21 professionals and patient representatives. A systematic literature review was performed, including dual appraisal of all citations. The GRADE methodology was used to extract, summarize, and assess the evidence. Multiple in-person meetings were held to rank outcomes, discuss evidence, complete evidence-to-decision frameworks, and formulate recommendations. Final recommendations were unanimously supported by all panel members. Results: Six studies, including 758 children, formed the evidence base for the recommendations. Given the scarcity of the available evidence and various designs of studies in children with cancer, additional evidence was extracted from adult oncology guidelines, and shared expert opinions were utilized. In total, 14 recommendations were formulated of which multiple result in changes in current policy and standard of practice in the Netherlands. Topics covered in this guideline are swimming, having pets, visiting the zoo or farm, performing sports or high-velocity events, attending school or kindergarten, and use of public transport. This guideline is not intended to provide recommendations for patients after end of treatment, for palliative care settings, or for children undergoing a stem cell transplantation. Conclusions: In this clinical practice guideline, we provide recommendations regarding restrictions in daily life in children with cancer. These include evidence-based recommendations and, in the absence of sufficient evidence, recommendations based on expert evidence. With these recommendations, we provide guidance for clinicians, children, and parents and contribute to improving quality of life for children with cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. NOTCH1 fusion genes in pediatric T-cell lymphoblastic lymphoma hallmark a common high-risk subgroup with blood TARC levels as possible diagnostic biomarker

Author

Kroeze, Emma, primary, Kleisman, Michelle M, additional, Kester, Lennart A, additional, Scheijde-Vermeulen, Marijn A, additional, Sonneveld, Edwin, additional, Buijs-Gladdines, Jessica GC, additional, Hagleitner, Melanie M, additional, Meyer-Wentrup, Friederike AG, additional, Veening, Margreet A, additional, Beishuizen, Auke, additional, Meijerink, Jules PP, additional, Loeffen, Jan LC, additional, and Kuiper, Roland P, additional

Published
2024
Full Text
View/download PDF

9. Nivolumab plus Brentuximab vedotin +/- bendamustine combination therapy: a safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma

Author

Unit Opleiding Aios, Infection & Immunity, CTI Boes, PMC Medisch specialisten, Zorg en O&O, Child Health, CTI Peperzak, Cancer, Greve, Patrick, Beishuizen, Auke, Hagleitner, Melanie, Loeffen, Jan, Veening, Margreet, Boes, Marianne, Peperzak, Victor, Diez, Claudius, Meyer-Wentrup, Friederike, Unit Opleiding Aios, Infection & Immunity, CTI Boes, PMC Medisch specialisten, Zorg en O&O, Child Health, CTI Peperzak, Cancer, Greve, Patrick, Beishuizen, Auke, Hagleitner, Melanie, Loeffen, Jan, Veening, Margreet, Boes, Marianne, Peperzak, Victor, Diez, Claudius, and Meyer-Wentrup, Friederike

Published
2023

10. 18F-FDG-PET/CT imaging in diagnostic workup of pediatric precursor B-cell lymphoblastic lymphoma

Author

MS Radiologie, Child Health, Arts-assistenten Radiologie, Brain, Cancer, Genetica, PMC Medisch specialisten, Kroeze, Emma, Padilla, Laura Arias, Burkhardt, Birgit, Attarbaschi, Andishe, von Mersi, Hannah, Kebudi, Rejin, Nievelstein, Rutger A.J., Tolboom, Nelleke, Hagleitner, Melanie M., Kuiper, Roland P., Beishuizen, Auke, Loeffen, Jan L.C., MS Radiologie, Child Health, Arts-assistenten Radiologie, Brain, Cancer, Genetica, PMC Medisch specialisten, Kroeze, Emma, Padilla, Laura Arias, Burkhardt, Birgit, Attarbaschi, Andishe, von Mersi, Hannah, Kebudi, Rejin, Nievelstein, Rutger A.J., Tolboom, Nelleke, Hagleitner, Melanie M., Kuiper, Roland P., Beishuizen, Auke, and Loeffen, Jan L.C.

Published
2023

12. SLC7A8 coding for LAT2 is associated with early disease progression in osteosarcoma and transports doxorubicin

Author

Hurkmans, Evelien G. E., primary, Koenderink, Jan B., additional, van den Heuvel, Jeroen J. M. W., additional, Versleijen-Jonkers, Yvonne M. H., additional, Hillebrandt-Roeffen, Melissa H. S., additional, Groothuismink, Johanne M., additional, Vos, Hanneke I., additional, van der Graaf, Winette T. A., additional, Flucke, Uta, additional, Muradjan, Grigor, additional, Schreuder, Hendrik W. B., additional, Hagleitner, Melanie M., additional, Brunner, Han G., additional, Gelderblom, Hans, additional, Cleton-Jansen, Anne-Marie, additional, Guchelaar, Henk-Jan, additional, de Bont, Eveline S. J. M., additional, Touw, Daan J., additional, Nijhoff, G. Jan, additional, Kremer, Leontien C. M., additional, Caron, Huib, additional, Windsor, Rachael, additional, Patiño-García, Ana, additional, González-Neira, Anna, additional, Saletta, Federica, additional, McCowage, Geoff, additional, Nagabushan, Sumanth, additional, Catchpoole, Daniel, additional, te Loo, D. Maroeska W. M., additional, and Coenen, Marieke J. H., additional

Published
2022
Full Text
View/download PDF

14. Pediatric Precursor B-Cell Lymphoblastic Malignancies: From Extramedullary to Medullary Involvement

Author

Kroeze, Emma, primary, Arias Padilla, Laura, additional, Bakker, Max, additional, Boer, Judith M., additional, Hagleitner, Melanie M., additional, Burkhardt, Birgit, additional, Mori, Takeshi, additional, Attarbaschi, Andishe, additional, Verdú-Amorós, Jaime, additional, Pillon, Marta, additional, Anderzhanova, Liliya, additional, Kabíčková, Edita, additional, Chiang, Alan K. S., additional, Kebudi, Rejin, additional, Mellgren, Karin, additional, Lazic, Jelena, additional, Jazbec, Janez, additional, Meijerink, Jules P. P., additional, Beishuizen, Auke, additional, and Loeffen, Jan L. C., additional

Published
2022
Full Text
View/download PDF

15. Pediatric Precursor B-Cell Lymphoblastic Malignancies:From Extramedullary to Medullary Involvement

Author

Kroeze, Emma, Arias Padilla, Laura, Bakker, Max, Boer, Judith M., Hagleitner, Melanie M., Burkhardt, Birgit, Mori, Takeshi, Attarbaschi, Andishe, Verdú-Amorós, Jaime, Pillon, Marta, Anderzhanova, Liliya, Kabíčková, Edita, Chiang, Alan K.S., Kebudi, Rejin, Mellgren, Karin, Lazic, Jelena, Jazbec, Janez, Meijerink, Jules P.P., Beishuizen, Auke, Loeffen, Jan L.C., Kroeze, Emma, Arias Padilla, Laura, Bakker, Max, Boer, Judith M., Hagleitner, Melanie M., Burkhardt, Birgit, Mori, Takeshi, Attarbaschi, Andishe, Verdú-Amorós, Jaime, Pillon, Marta, Anderzhanova, Liliya, Kabíčková, Edita, Chiang, Alan K.S., Kebudi, Rejin, Mellgren, Karin, Lazic, Jelena, Jazbec, Janez, Meijerink, Jules P.P., Beishuizen, Auke, and Loeffen, Jan L.C.

Abstract

B-cell lymphoblastic lymphoma (BCP-LBL) and B-cell acute lymphoblastic leukemia (BCP-ALL) are the malignant counterparts of immature B-cells. BCP-ALL is the most common hematological malignancy in childhood, while BCP-LBL accounts for only 1% of all hematological malignancies in children. Therefore, BCP-ALL has been well studied and treatment protocols have changed over the last decades, whereas treatment for BCP-LBL has stayed roughly the same. Clinical characteristics of 364 pediatric patients with precursor B-cell malignancies were studied, consisting of BCP-LBL (n = 210) and BCP-ALL (n = 154) patients. Our results indicate that based on the clinical presentation of disease, B-cell malignancies probably represent a spectrum ranging from complete isolated medullary disease to apparent complete extramedullary disease. Hepatosplenomegaly and peripheral blood involvement are the most important discriminators, as both seen in 80% and 95% of the BCP-ALL patients and in 2% of the BCP-LBL patients, respectively. In addition, we show that the overall survival rates in this cohort differ significantly between BCP-LBL and BCP-ALL patients aged 1–18 years (p = 0.0080), and that the outcome for infants (0–1 years) with BCP-LBL is significantly decreased compared to BCP-LBL patients of all other pediatric ages (p < 0.0001).

Published
2022

16. High Prevalence of Constitutional Mismatch Repair Deficiency in a Pediatric T-cell Lymphoblastic Lymphoma Cohort

Author

Genetica, Genetica Klinische Genetica, Child Health, Cancer, Zorg en O&O, PMC Medisch specialisten, Kroeze, Emma, Weijers, Dilys D., Hagleitner, Melanie M., De Groot-Kruseman, Hester A., Jongmans, Marjolijn C.J., Kuiper, Roland P., Pieters, Rob, Meijerink, Jules P.P., Loeffen, Jan L.C., Genetica, Genetica Klinische Genetica, Child Health, Cancer, Zorg en O&O, PMC Medisch specialisten, Kroeze, Emma, Weijers, Dilys D., Hagleitner, Melanie M., De Groot-Kruseman, Hester A., Jongmans, Marjolijn C.J., Kuiper, Roland P., Pieters, Rob, Meijerink, Jules P.P., and Loeffen, Jan L.C.

Published
2022

17. Severe toxicity free survival: physician-derived definitions of unacceptable long-term toxicities following acute lymphocytic leukaemia

Author

Andrés-Jensen, Liv, primary, Attarbaschi, Andishe, additional, Bardi, Edit, additional, Barzilai-Birenboim, Shlomit, additional, Bhojwani, Deepa, additional, Hagleitner, Melanie M, additional, Halsey, Christina, additional, Harila-Saari, Arja, additional, van Litsenburg, Raphaele R L, additional, Hudson, Melissa M, additional, Jeha, Sima, additional, Kato, Motohiro, additional, Kremer, Leontien, additional, Mlynarski, Wojciech, additional, Möricke, Anja, additional, Pieters, Rob, additional, Piette, Caroline, additional, Raetz, Elizabeth, additional, Ronceray, Leila, additional, Toro, Claudia, additional, Grazia Valsecchi, Maria, additional, Vrooman, Lynda M, additional, Weinreb, Sigal, additional, Winick, Naomi, additional, Schmiegelow, Kjeld, additional, Adams, Madeline R, additional, Andres-Jensen, Liv, additional, Baust, Katja, additional, Boesten, Tineke, additional, Calaminus, Gabriele, additional, Conyers, Rachel, additional, Darlington, Anne-Sophie, additional, de Ville, Maëlle, additional, Escherich, Gabriele, additional, Hagleitner, Melanie, additional, Hou, Jen-Yin, additional, Huang, Ting-Huan, additional, Hudson, Melissa, additional, Jenney, Meriel, additional, Krawczuk-Rybak, Maryna, additional, Kremer, Leontine, additional, Lautem, Melchior, additional, Liu, Hse-Che, additional, Lopez Lopez, Elixabet, additional, Mateos, Marion, additional, Muszynska-Roslan, Katarzyna, additional, Niinimaki, Riitta, additional, Trahair, Toby, additional, Valsecchi, Maria Grazia, additional, van der Sluis, Inge, additional, van Litsenburg, Raphaële, additional, Vrooman, Lynda, additional, Wiener, Andreas, additional, Yano, Michihiro, additional, Yeh, Ting-Chi, additional, and Zapotocka, Ester, additional

Published
2021
Full Text
View/download PDF

20. Severe toxicity free survival : physician-derived definitions of unacceptable long-term toxicities following acute lymphocytic leukaemia

Author

Andrés-Jensen, Liv, Attarbaschi, Andishe, Bardi, Edit, Barzilai-Birenboim, Shlomit, Bhojwani, Deepa, Hagleitner, Melanie M., Halsey, Christina, Harila-Saari, Arja, van Litsenburg, Raphaele R. L., Hudson, Melissa M., Jeha, Sima, Kato, Motohiro, Kremer, Leontien, Mlynarski, Wojciech, Möricke, Anja, Pieters, Rob, Piette, Caroline, Raetz, Elizabeth, Ronceray, Leila, Toro, Claudia, Valsecchi, Maria Grazia, Vrooman, Lynda M., Weinreb, Sigal, Winick, Naomi, Schmiegelow, Kjeld, Andrés-Jensen, Liv, Attarbaschi, Andishe, Bardi, Edit, Barzilai-Birenboim, Shlomit, Bhojwani, Deepa, Hagleitner, Melanie M., Halsey, Christina, Harila-Saari, Arja, van Litsenburg, Raphaele R. L., Hudson, Melissa M., Jeha, Sima, Kato, Motohiro, Kremer, Leontien, Mlynarski, Wojciech, Möricke, Anja, Pieters, Rob, Piette, Caroline, Raetz, Elizabeth, Ronceray, Leila, Toro, Claudia, Valsecchi, Maria Grazia, Vrooman, Lynda M., Weinreb, Sigal, Winick, Naomi, and Schmiegelow, Kjeld

Abstract

5-year overall survival rates have surpassed 90% for childhood acute lymphocytic leukaemia, but survivors are at risk for permanent health sequelae. Although event-free survival appropriately represents the outcome for cancers with poor overall survival, this metric is inadequate when cure rates are high but challenged by serious, persistent complications. Accordingly, a group of experts in paediatric haematology-oncology, representative of 17 international acute lymphocytic leukaemia study groups, launched an initiative to construct a measure, designated severe toxicity-free survival (STFS), to quantify the occurrence of physician-prioritised toxicities to be integrated with standard cancer outcome reporting. Five generic inclusion criteria (not present before cancer diagnosis, symptomatic, objectifiable, of unacceptable severity, permanent, or requiring unacceptable treatments) were used to assess 855 health conditions, which resulted in inclusion of 21 severe toxicities. Consensus definitions were reached through a modified Delphi process supplemented by two additional plenary meetings. The 21 severe toxicities include severe adverse health conditions that substantially affect activities of daily living and are refractory to therapy (eg, refractory seizures), are without therapeutic options (eg, blindness), or require substantially invasive treatment (eg, cardiac transplantation). Incorporation of STFS assessment into clinical trials has the potential to improve and diversify treatment strategies, focusing not only on traditional outcome events and overall survival but also the frequencies of the most severe toxicities. The two major aims of this Review were to: prioritise and define unacceptable long-term toxicity for patients with childhood acute lymphocytic leukaemia, and define how these toxicities should be combined into a composite quantity to be integrated with other reported outcomes. Although STFS quantifies the clinically unacceptable health tradeoff fo

Published
2021
Full Text
View/download PDF

22. Analysis of Drug Metabolizing Gene Panel in Osteosarcoma Patients Identifies Association Between Variants inSULT1E1, CYP2B6andCYP4F8and Methotrexate Levels and Toxicities

Author

Hurkmans, E.G.E., Klumpers, M.J., Vermeulen, S.H., Hagleitner, Melanie M., Flucke, U.E., Schreuder, H.W.B., Coenen, M.J.H., Loo, D.M.W.M. te, Hurkmans, E.G.E., Klumpers, M.J., Vermeulen, S.H., Hagleitner, Melanie M., Flucke, U.E., Schreuder, H.W.B., Coenen, M.J.H., and Loo, D.M.W.M. te

Abstract

Contains fulltext : 222069.pdf (publisher's version ) (Open Access)

Published
2020

24. Analysis of Drug Metabolizing Gene Panel in Osteosarcoma Patients Identifies Association Between Variants in SULT1E1, CYP2B6 and CYP4F8 and Methotrexate Levels and Toxicities

Author

Hurkmans, Evelien G. E., primary, Klumpers, Marije J., additional, Vermeulen, Sita H., additional, Hagleitner, Melanie M., additional, Flucke, Uta, additional, Schreuder, H. W. Bart, additional, Gelderblom, Hans, additional, Bras, Johannes, additional, Guchelaar, Henk-Jan, additional, Coenen, Marieke J. H., additional, and te Loo, D. Maroeska W. M., additional

Published
2020
Full Text
View/download PDF

26. Liver involvement in pediatric Hodgkin lymphoma: A systematic review by an international collaboration on Staging Evaluation and Response Criteria Harmonization (SEARCH) for Children, Adolescent, and Young Adult Hodgkin Lymphoma (CAYAHL)

Author

Hagleitner, Melanie M., primary, Metzger, Monika L., additional, Flerlage, Jamie E., additional, Kelly, Kara M., additional, Voss, Stephan D., additional, Kluge, Regine, additional, Kurch, Lars, additional, Cho, Steve, additional, Mauz‐Koerholz, Christine, additional, and Beishuizen, Auke, additional

Published
2020
Full Text
View/download PDF

28. Dosage of 6-Mercaptopurine in Relation to Genetic TPMTand ITPAVariants: Toward Individualized Pediatric Acute Lymphoblastic Leukemia Maintenance Treatment

Author

Kouwenberg, Theodorus W., van den Bosch, Bianca J.C., Bierau, Jörgen, te Loo, Dunja Maroeska W.M., Coenen, Marieke J.H., and Hagleitner, Melanie M.

Abstract

6-mercaptopurine (6-MP) is the mainstay in pediatric acute lymphoblastic leukemia (ALL) maintenance treatment. Variants in genes coding for thiopurine S-methyl transferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) are known to influence 6-MP metabolism. We determined TPMTand ITPAgenotype and enzyme activity and the mean 6-MP doses during maintenance treatment in 40 children treated for ALL according to the Dutch Childhood Oncology Group (DCOG)-ALL11 protocol in the Radboudumc Amalia Children’s Hospital, Nijmegen, The Netherlands. Patients with genetic variants in TPMT(N=3) had significantly lower TPMT enzyme activity (mean 0.46 vs. 0.72 µmol/mmol hemoglobin/h, P=0.005). Although the difference was not statistically significant, they were treated with lower mean 6-MP doses (28.1 mg/m2[SD 25.5 mg/m2] vs. 41.3 mg/m2[SD 17.2 mg/m2], P=0.375). In patients with genetic ITPAvariants (N=21), ITPA enzyme activity was significantly lowered (mean 3.67 vs. 6.84 mmol/mmol hemoglobin/h, P<0.0005). The mean 6-MP doses did not differ between patients with and without variants in ITPA(40.0 mg/m2[SD 20.3 mg/m2] vs. 40.6 mg/m2[SD 14.9 mg/m2], P=0.663). The TPMTgenotype, but not the ITPAgenotype, should be considered as part of standard evaluation before starting ALL maintenance treatment.

Published
2020
Full Text
View/download PDF

29. A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment

Author

Hagleitner, Melanie M., primary, Coenen, Marieke J.H., additional, Gelderblom, Hans, additional, Makkinje, Remco R., additional, Vos, Hanneke I., additional, de Bont, Eveline S.J.M., additional, van der Graaf, Winette T.A., additional, Schreuder, H.W. Bart, additional, Flucke, Uta, additional, van Leeuwen, Frank N., additional, Hoogerbrugge, Peter M., additional, Guchelaar, Henk-Jan, additional, and te Loo, Dunja M.W.M, additional

Published
2015
Full Text
View/download PDF

30. Influence of Genetic Variants in TPMT and COMT Associated with Cisplatin Induced Hearing Loss in Patients with Cancer: Two New Cohorts and a Meta-Analysis Reveal Significant Heterogeneity between Cohorts

Author

Hagleitner, Melanie M., primary, Coenen, Marieke J. H., additional, Patino-Garcia, Ana, additional, de Bont, Eveline S. J. M., additional, Gonzalez-Neira, Anna, additional, Vos, Hanneke I., additional, van Leeuwen, Frank N., additional, Gelderblom, Hans, additional, Hoogerbrugge, Peter M., additional, Guchelaar, Henk-Jan, additional, and te Loo, Maroeska W. M., additional

Published
2014
Full Text
View/download PDF

39. 18 F-FDG-PET/CT imaging in diagnostic workup of pediatric precursor B-cell lymphoblastic lymphoma.

Author

Kroeze E, Padilla LA, Burkhardt B, Attarbaschi A, von Mersi H, Kebudi R, Nievelstein RAJ, Tolboom N, Hagleitner MM, Kuiper RP, Beishuizen A, and Loeffen JLC

Subjects
Humans, Child, Positron Emission Tomography Computed Tomography, Retrospective Studies, Diagnostic Imaging, Fluorodeoxyglucose F18, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma diagnostic imaging
Abstract

18 F-fluorodeoxyglucose-positron emission tomography/computed tomography (PET/CT) imaging is currently not used in standard diagnostics for B-cell precursor lymphoblastic lymphoma (BCP-LBL), and it is unknown whether PET/CT imaging would lead to agreement between detection of lesions with the gold standard imaging methods. Therefore, we performed a retrospective cohort study in which we included 32 pediatric BCP-LBL patients and determined localizations by reviewing local imaging reports. There was a disagreement between protocol-based imaging and PET/CT in 59% of the patients, and the discrepancies mostly comprise of additional lesions detected with PET/CT, typically in lymph node and bone or the absence of bone marrow involvement with PET/CT. If PET/CT was leading in determining definite stage of disease, this would lead to a different stage and therapy branch in 31% and 28% of the patients, respectively., (© 2023 Wiley Periodicals LLC.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results